The Effects of BRCA1 Expression on the Chemosensitivity of Gastric Cancer Cells to Platinum Agents

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jun 13

PMID 31186713

Citations 3

Authors

Geon Kim

Jisu Kim

Su-Young Han

In Gyu Hwang

Hee Sung Kim

Hyeyoung Min

Affiliations

Soon will be listed here.

Abstract

Breast cancer type 1 susceptibility protein (BRCA1) is a tumor suppressor gene that encodes a nuclear phosphoprotein, which is involved in homologous recombination to repair DNA double strand breaks and maintain genome stability. When BRCA1 is mutated or altered, DNA damage may not be effectively repaired, which leads to DNA replication errors and cancer growth. Accordingly, people carrying a mutation in the BRCA1 gene possess an increased risk of several types of cancer, including breast and ovarian cancer. Previous clinical studies have reported an association between BRCA1 expression level and the incidence of gastric cancer; however, to the best of our knowledge, an study has not been performed to support these clinical observations. Therefore, the present study evaluated BRCA1 expression levels in gastric cancer cell lines. In addition, the IC values of cisplatin and oxaliplatin in each cell line were determined to investigate a potential correlation between BRCA1 expression level and chemosensitivity to platinum agents. The present results revealed that the BRCA1 expression level in gastric cancer is variable and associated with the treatment response to platinum-based chemotherapy. This suggests that BRCA1 may serve as a therapeutic marker for platinum-based chemotherapy in gastric cancer.

Citing Articles

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer.

Chen H, Hu Y, Zhuang Z, Wang D, Ye Z, Jing J Cancers (Basel). 2023; 15(21).

PMID: 37958290 PMC: 10647262. DOI: 10.3390/cancers15215114.

TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.

Zhang S, Cao M, Yan S, Liu Y, Fan W, Cui Y Int J Biol Sci. 2022; 18(7):2962-2979.

PMID: 35541909 PMC: 9066100. DOI: 10.7150/ijbs.71283.

PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.

Lv D, Xing C, Cao L, Zhuo Y, Wu T, Gao N Oncol Lett. 2020; 19(2):1223-1234.

PMID: 31966052 PMC: 6956287. DOI: 10.3892/ol.2019.11221.

References

Fleisher A, Esteller M, Wang S, Tamura G, Suzuki H, Yin J . Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 1999; 59(5):1090-5. View

Nehme A, Baskaran R, Nebel S, Fink D, Howell S, Wang J . Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. Br J Cancer. 1999; 79(7-8):1104-10. PMC: 2362240. DOI: 10.1038/sj.bjc.6690176. View

Strathdee G, Mackean M, Illand M, Brown R . A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999; 18(14):2335-41. DOI: 10.1038/sj.onc.1202540. View

Yamamoto H, Yoshida T, Terada M, Itoh F, Imai K, Perucho M . Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 1999; 116(6):1348-57. DOI: 10.1016/s0016-5085(99)70499-3. View

Caldas C, Carneiro F, Lynch H, Yokota J, Wiesner G, Powell S . Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999; 36(12):873-80. PMC: 1734270. View

Wu M, Lee C, Shun C, Wang H, Lee W, Chang M . Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer. 2000; 27(4):403-11. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

Wang Y, Cortez D, Yazdi P, NEFF N, Elledge S, Qin J . BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 2000; 14(8):927-39. PMC: 316544. View

Pinto M, Oliveira C, Machado J, Cirnes L, Tavares J, Carneiro F . MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest. 2001; 80(12):1915-23. DOI: 10.1038/labinvest.3780201. View

10.

Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T . Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene. 2001; 20(34):4640-9. DOI: 10.1038/sj.onc.1204625. View

11.

Zdraveski Z, Mello J, Farinelli C, Essigmann J, Marinus M . MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem. 2001; 277(2):1255-60. DOI: 10.1074/jbc.M105382200. View

12.

Joo W, Jeffrey P, Cantor S, Finnin M, Livingston D, Pavletich N . Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev. 2002; 16(5):583-93. PMC: 155350. DOI: 10.1101/gad.959202. View

13.

Mueller C, Roskelley C . Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 2003; 5(1):45-52. PMC: 154136. DOI: 10.1186/bcr557. View

14.

Rosen E, Fan S, Pestell R, Goldberg I . BRCA1 gene in breast cancer. J Cell Physiol. 2003; 196(1):19-41. DOI: 10.1002/jcp.10257. View

15.

Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S . Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev. 2004; 30(5):451-9. DOI: 10.1016/j.ctrv.2004.01.001. View

16.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

17.

Zimmermann T, Zeizinger M, Burda J . Cisplatin interaction with cysteine and methionine, a theoretical DFT study. J Inorg Biochem. 2005; 99(11):2184-96. DOI: 10.1016/j.jinorgbio.2005.07.021. View

18.

Bacani J, Zwingerman R, Di Nicola N, Spencer S, Wegrynowski T, Mitchell K . Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn. 2005; 7(4):465-77. PMC: 1888489. DOI: 10.1016/S1525-1578(10)60577-6. View

19.

Ajani J . Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005; 10 Suppl 3:49-58. DOI: 10.1634/theoncologist.10-90003-49. View

20.

Chen X, Zhang W, Lin X, Wang J . Genetic instability of BRCA1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population. World J Gastroenterol. 2006; 12(26):4246-9. PMC: 4087384. DOI: 10.3748/wjg.v12.i26.4246. View